1 / 2

Étude FIRE-3

Étude FIRE-3. Résultats selon le statut RAS (KRAS/NRAS exons 2, 3, 4). ESMO 2013 - D’après Stintzing S et al., LBA 17, actualisé. La Lettre du Cancérologue. Étude FIRE-3. Survie globale (RAS sauvage). Événements n/N (%). Médiane (mois). 1,0. IC 95. 91/171 (53,2 %). 33,1.

ledell
Download Presentation

Étude FIRE-3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Étude FIRE-3 Résultats selon le statut RAS (KRAS/NRAS exons 2, 3, 4) • ESMO 2013 - D’après Stintzing S et al., LBA 17, actualisé • La Lettre du Cancérologue

  2. Étude FIRE-3 Survie globale (RAS sauvage) Événementsn/N (%) Médiane(mois) 1,0 IC95 91/171 (53,2 %) 33,1 24,5-39,4 FOLFIRI + cétuximab 0,75 110/171 (64,3 %) 25,6 22,7-28,6 FOLFIRI + bévacizumab HR = 0,70 ; IC95 : 0,53-0,92 p = 0,011 0,50 Probabilité de survie Δ = 7,5 mois 0,25 0 0 12 24 36 48 60 72 Patients à risque (n) • La Lettre du Cancérologue • ESMO 2013 - D’après Stintzing S et al., LBA 17, actualisé 171 171 128 127 71 68 39 26 20 9 6 1

More Related